Cisplatin liposomal - Regulon

Drug Profile

Cisplatin liposomal - Regulon

Alternative Names: Lipoplatin; Nanoplatin for NSCLC - Regulon

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator Regulon
  • Developer Centre Hospitalier Universitaire Vaudois; Regulon
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II/III Pancreatic cancer
  • Phase II Breast cancer; Gastric cancer
  • Phase I Malignant pleural effusion
  • Preclinical Glioblastoma
  • No development reported Bladder cancer; Head and neck cancer; Ovarian cancer

Most Recent Events

  • 01 Nov 2016 Regulon suspends phase II/III trial in Pancreatic cancer in Greece (EudraCT2006-005485-40)
  • 03 Sep 2016 Adverse events and efficacy data from a phase II trial in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
  • 01 Jan 2016 Phase-I clinical trials in Malignant pleural effusion in Switzerland (IV) (NCT02702700)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top